

DAFTAR PUSTAKA

- Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabetic Medicine : A Journal of the British Diabetic Association*, 23(5), 469–480. <https://doi.org/10.1111/j.1464-5491.2006.01858.x>
- Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C. J., Virani, S. S., Williams, K. A. S., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 74(10), e177–e232. <https://doi.org/10.1016/j.jacc.2019.03.010>
- Attia, G. M., Almouteri, M. M., & Alnakhli, F. T. (2023). Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility. *Cureus*, 15(8), e44493. <https://doi.org/10.7759/cureus.44493>
- Barnett, C. F., & Machado, R. F. (2006). Sildenafil in the treatment of pulmonary hypertension. *Vascular Health and Risk Management*, 2(4), 411–422. <https://doi.org/10.2147/vhrm.2006.2.4.411>
- BPOM. (2018). *Peraturan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia Nomor 26 TAHUN 2018 tentang Pelayanan Perizinan Berusaha Terintegrasi secara Elektronik Sektor Obat dan Makanan*. Jakarta: Badan Pengawas Obat dan Makanan.
- Cahyono, A., Rahman, M. A., & Widjiati, W. (2026). Sildenafil and metformin combination attenuates monocrotaline- induced pulmonary hypertension via TNF- α and ERK1 / 2 modulation. 14(1), 0–3.
- Chandola, T., Brunner, E., & Marmot, M. (2006). Chronic stress at work and the metabolic syndrome: prospective study. *BMJ (Clinical Research Ed.)*, 332(7540), 521–525. <https://doi.org/10.1136/bmj.38693.435301.80>

- Danés, I., Agustí, A., Vallano, A., Alerany, C., Martínez, J., Bosch, J. A., Ferrer, A., Gratacós, L., Pérez, A., Olmo, M., Marron, S. M. C., Valderrama, A., & Bonafont, X. (2014). Outcomes of off-label drug uses in hospitals: a multicentric prospective study. *European Journal of Clinical Pharmacology*, 70(11), 1385–1393. <https://doi.org/10.1007/s00228-014-1746-2>
- Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocrine Reviews*, 33(6), 981–1030. <https://doi.org/10.1210/er.2011-1034>
- Dresser, R., & Frader, J. (2009). Off-label prescribing: a call for heightened professional and government oversight. *The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics*, 37(3), 396,476-486. <https://doi.org/10.1111/j.1748-720X.2009.00408.x>
- Driyah, S., Oemiati, R., Rustika, R., & Nova, S. H. (2019). Prediktor Sindrom Metabolik : Studi Kohor Prospektif Selama. *Media Litbangkes*, 3(September), 215–224.
- FDA. (2023). *Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14)] . Pediatric Patients (.*
- FDA. (2025). *Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers Guidance for Industry (Issue Xxxx).*
- Fotouhi, F., Hashemi, H., Yekta, A., Niroomand, M., Esmaeili, M., Norouzirad, R., Vaghefi, N., & Khabazkhoob, M. (2025). The prevalence of metabolic syndrome and its economic inequality in an elderly population. *Scientific Reports*, 15(1), 40626. <https://doi.org/10.1038/s41598-025-24227-w>
- Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., & Simonneau, G. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. *The New England Journal of Medicine*, 353(20), 2148–2157.

<https://doi.org/10.1056/NEJMoa050010>

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/P CNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, 139(25), e1082–e1143.

<https://doi.org/10.1161/CIR.0000000000000625>

Guess, J., Beltran, T. H., & Choi, Y. S. (2023). Prediction of Metabolic Syndrome in U.S. Adults Using Homeostasis Model Assessment-Insulin Resistance. *Metabolic Syndrome and Related Disorders*, 21(3), 156–162.

<https://doi.org/10.1089/met.2022.0097>

Herman, R., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2022). Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. *International Journal of Molecular Sciences*, 23(3). <https://doi.org/10.3390/ijms23031264>

Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., Ferreira, D. S., Ghofrani, H. A., Giannakoulas, G., Kiely, D. G., Mayer, E., Meszaros, G., Nagavci, B., Olsson, K. M., Pepke-Zaba, J., ... Rosenkranz, S. (2023). 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *The European Respiratory Journal*, 61(1).

<https://doi.org/10.1183/13993003.00879-2022>

Idrees Butt, D. T., Shazdi, K., Anjum, F., Ahmar Yaqoob, M., Mohsin Sattar, M. M., & Umer, A. (2024). Review the Current Therapeutic Interventions and Management Strategies That Target Both Mental Health and Metabolic Abnormalities in Individuals. *Journal of Population Therapeutics & Clinical Pharmacology*, 31(01), 418–422. <https://doi.org/10.53555/jptcp.v31i1.4019>

- Kemenkes. (2018). Laporan Riskesdas 2018 Nasional.pdf. In *Lembaga Penerbit Balitbangkes* (p. hal 156).
- Kemenkes RI. (2020). *Permenkes No 3 Tahun 2020 Tentang Klasifikasi dan Perizinan Rumah Sakit. Tentang Klasifikasi Dan Perizinan Rumah Sakit*. 3, 1–80.
- Kemenkes RI. (2022). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 24 Tahun 2022 Tentang Rekam Medis*. 9, 356–363. 829, 1–19.
- Kivimäki, M., Virtanen, M., Kawachi, I., Nyberg, S. T., Alfredsson, L., Batty, G. D., Bjorner, J. B., Borritz, M., Brunner, E. J., Burr, H., Dragano, N., Ferrie, J. E., Fransson, E. I., Hamer, M., Heikkilä, K., Knutsson, A., Koskenvuo, M., Madsen, I. E. H., Nielsen, M. L., ... Jokela, M. (2015). Long working hours, socioeconomic status, and the risk of incident type 2 diabetes: a meta-analysis of published and unpublished data from 222 120 individuals. *The Lancet Diabetes & Endocrinology*, 3(1), 27–34. [https://doi.org/10.1016/S2213-8587\(14\)70178-0](https://doi.org/10.1016/S2213-8587(14)70178-0)
- Lann, D., & LeRoith, D. (2007). Insulin resistance as the underlying cause for the metabolic syndrome. *The Medical Clinics of North America*, 91(6), 1063–1077, viii. <https://doi.org/10.1016/j.mcna.2007.06.012>
- Lenk, C., & Duttge, G. (2014). Ethical and legal framework and regulation for off-label use: European perspective. *Therapeutics and Clinical Risk Management*, 10, 537–546. <https://doi.org/10.2147/TCRM.S40232>
- Lestari, D. D. (2020). *Studi Penggunaan Obat pada Pasien dengan Gangguan Endokrin, Gastroenterik dan Infeksi, Fakultas Farmasi UMP, 2020*.
- Lipsky, B. A., Dryden, M., Gottrup, F., Nathwani, D., Seaton, R. A., & Stryja, J. (2016). Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. *Journal of Antimicrobial Chemotherapy*, 71(11), 3026–3035. <https://doi.org/10.1093/jac/dkw287>
- Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003). Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. *The Cochrane Database of Systematic Reviews*,

- 3, CD003053. <https://doi.org/10.1002/14651858.CD003053>
- Mahendra, A. R., Surakarta, U. A., & Nacl, P. (2023). *Penerapan Perawatan Luka Dengan Nacl Pada Pasien Dengan Ulkus Diabetik Di Puskesmas Pucangsawit*. 2 no. 9, 302–309.
- Maidarti, M., Harzif, A. K., Shadrina, A., Ummah, N., & Permadi, W. (2025). Executive summary: indonesian guidelines on polycystic ovary syndrome management. *Obstet Gynecol Sci*, 68(3), 221–236. <https://doi.org/10.5468/ogs.24288>
- Mellitus, D. (1999). Definition , Diagnosis and Classification of Diabetes Mellitus and its Complications Part 1 : Diagnosis and Classification of. *World Health*, 15(7), 539–553. [https://doi.org/10.1002/\(SICI\)1096-9136\(199807\)15:7<539::AID-DIA668>3.0.CO;2-S](https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S)
- Nikolic Turnic, T., Jakovljevic, V., Strizhkova, Z., Polukhin, N., Ryaboy, D., Kartashova, M., Korenkova, M., Kolchina, V., & Reshetnikov, V. (2024). The Association between Marital Status and Obesity: A Systematic Review and Meta-Analysis. *Diseases (Basel, Switzerland)*, 12(7). <https://doi.org/10.3390/diseases12070146>
- Nolan, P. B., Carrick-Ranson, G., Stinear, J. W., Reading, S. A., & Dalleck, L. C. (2017). Prevalence of metabolic syndrome and metabolic syndrome components in young adults: A pooled analysis. *Preventive Medicine Reports*, 7, 211–215. <https://doi.org/10.1016/j.pmedr.2017.07.004>
- Noubiap, J. J., Nansseu, J. R., Lontchi-Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. N., Tianyi, F. L., Foka, A. J., Ndoadoumgue, A. L., & Bigna, J. J. (2022). Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. *The Lancet. Child & Adolescent Health*, 6(3), 158–170. [https://doi.org/10.1016/S2352-4642\(21\)00374-6](https://doi.org/10.1016/S2352-4642(21)00374-6)
- Palaniappan, L. P., Wong, E. C., Shin, J. J., Fortmann, S. P., & Lauderdale, D. S. (2011). Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. *International Journal of Obesity (2005)*, 35(3), 393–400. <https://doi.org/10.1038/ijo.2010.152>

- Patial, R., Batta, I., Thakur, M., Chander Sobti, R., & K. Agrawal, D. (2024). Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome. *Archives of Internal Medicine Research*, 7(4), 273–283. <https://doi.org/10.26502/aimr.0184>
- Prawira, Y., & Yanuarso, P. B. (2016). Sildenafil Sebagai Pilihan Terapi Hipertensi Pulmonal Pascabedah Jantung Koreksi Penyakit Jantung Bawaan pada Anak. *Sari Pediatri*, 11(6), 456. <https://doi.org/10.14238/sp11.6.2010.456-462>
- Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006). Off-label prescribing among office-based physicians. *Archives of Internal Medicine*, 166(9), 1021–1026. <https://doi.org/10.1001/archinte.166.9.1021>
- Ranasinghe, P., Mathangasinghe, Y., Jayawardena, R., Hills, A. P., & Misra, A. (2017). Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. *BMC Public Health*, 17(1), 101. <https://doi.org/10.1186/s12889-017-4041-1>
- Rantung, sally kunu jeanny. (2025). The Relationship Between Family Support and Quality Of Life in Adolescents With Thalassaemia Major. *Holistic Nursing Plus*, 3(1), 62–71. <https://doi.org/10.58439/hnp.v3i1.327>
- Rochlani, Y., Pothineni, N. V., Kovelamudi, S., & Mehta, J. L. (2017). Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Therapeutic Advances in Cardiovascular Disease*, 11(8), 215–225. <https://doi.org/10.1177/1753944717711379>
- Rusli. (2018). *Farmasi Klinik : Kementrian Kesehatan Republik Indonesia*.
- Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021). Off-Label Medication: From a Simple Concept to Complex Practical Aspects. *International Journal of Environmental Research and Public Health*, 18(19). <https://doi.org/10.3390/ijerph181910447>
- Saklayen, M. G. (2018a). La epidemia mundial del síndrome metabólico. *Estados Unidos de América, Rev. Current Hypertension Reports*, 20(2), 1–2. <https://pubmed.ncbi.nlm.nih.gov/29480368/>
- Saklayen, M. G. (2018b). The Global Epidemic of the Metabolic Syndrome.

- Current Hypertension Reports*, 20(2), 12. <https://doi.org/10.1007/s11906-018-0812-z>
- Senneville, É., Albalawi, Z., van Asten, S. A., Abbas, Z. G., Allison, G., Aragón-Sánchez, J., Embil, J. M., Lavery, L. A., Alhasan, M., Oz, O., Uçkay, I., Urbančič-Rovan, V., Xu, Z.-R., & Peters, E. J. G. (2023). IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). *Clinical Infectious Diseases*, ciad527. <https://doi.org/10.1093/cid/ciad527>
- Setyaningrum, N., Gredynadita, V., & Gartina, S. (2017). *Penggunaan Obat Off-Label pada Anak di Apotek Kota Yogyakarta*. 4, 30–35. <https://doi.org/10.29208/jsfk.2017.4.1.169>
- Stafford, R. S. (2008). Regulating Off-Label Drug Use — Rethinking the Role of the FDA. *New England Journal of Medicine*, 358(14), 1427–1429. <https://doi.org/10.1056/nejmp0802107>
- Suhaema, & Herta Masthalina. (2015). Consumption Patterns with Occurrence of Metabolic Syndrome in Indonesia. *Jurnal Kesehatan Masyarakat Nasional*, 9(4), 340–347.
- Susilo, J., Kurniawati, I., Haswan, D., Zurroh, A. H. F., & Pratiwi, N. D. (2025). Menopause, Sindroma Metabolik dan Terapi Hormon. *Indonesian Journal of Midwifery (IJM)*, 8, 18–36.
- Swarup, S., Ahmed, I., Grigorova, Y., & Zeltser, R. (2025). *Metabolic Syndrome*.
- Teede, H. J., Tay, C. T., Laven, J., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., M Redman, L., A Boyle, J., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. *Fertility and Sterility*, 120(4), 767–793. <https://doi.org/10.1016/j.fertnstert.2023.07.025>
- Tuloli, T. S., Madania, M., Djuwarno, E. N., Hiola, F., & Hamzah, A. R. (2024). Gambaran Penggunaan Obat Off-Label Pada Pasien Pediatrik Rawat Inap Di RSUD Dr. Hasri Ainun Habibie Limboto. *Journal of Community and Clinical Pharmacy*, 1(3 SE-Articles), 8–15.

<https://doi.org/10.70075/jccp.v1i3.55>

Tuloli, T. S., Rasdianah, N., Makkulawu, A., Ramadani, D., Papeo, P., & Datau, M. (2022). *Gambaran Penggunaan Obat Off-Label Pada Pasien Pediatrik Rawat Inap di Rumah Sakit*. 2(2), 130–142.

<https://doi.org/10.37311/ijpe.v2i2.11449>

Viatrix. (1998). *Adults REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14)] . Pediatric Patients (.*

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E. J., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C. J., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A. S., ... Wright, J. T. J. (2018). 2017

ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical P. *Journal of the American College of Cardiology*, 71(19), e127–e248.

<https://doi.org/10.1016/j.jacc.2017.11.006>

Widiantini, W., & Tafal, Z. (2014). Aktivitas Fisik, Stres, dan Obesitas pada Pegawai Negeri Sipil. *Kesmas: National Public Health Journal*, 8(7), 325.

<https://doi.org/10.21109/kesmas.v0i0.374>

Wittich, C. M., Burkle, C. M., & Lanier, W. L. (2012). Ten common questions (and their answers) about off-label drug use. *Mayo Clinic Proceedings*, 87(10), 982–990. <https://doi.org/10.1016/j.mayocp.2012.04.017>